In today's edition of the Motley Fool's health-care show, Market Checkup, analysts Max Macaluso and David Williamson cover an FDA rejection for Merck, approvals for Johnson & Johnson, and a new partnership for AbbVie.
Two game-changing biotech stocks
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.